Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

SAB Biotherapeutics, Inc.

NASDAQ: SABS · Life Sciences · 2 alerts · CIK 1833214

Share price
$3.00Close, Nov 16
Market cap
$270M
Shares outstanding
90.09MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All SAB Biotherapeutics, Inc. filings on SEC EDGAR ↗

7:37 AM ET 10-Q
Financial Results

SAB Biotherapeutics Q3 2026 Results: Net Loss of $22.3M

SAB Biotherapeutics reported a net loss of $22.3 million for the third quarter of 2026, compared to a net income of $45.4 million in the prior year period, primarily due to a significant decrease in the non-cash gain from the change in fair value of warrant liabilities. Operating expenses increased substantially to $25.9 million as the company ramped up research and development activities.

Key figure
Net loss $22.3M
8:36 AM ET 8-K
Regulatory Approval

SAB Biotherapeutics Regulatory Approval

SAB Biotherapeutics announced that the FDA has granted Fast Track designation to SAB-142, a fully human anti-thymocyte immunoglobulin being developed for Stage 3 type 1 diabetes. The designation is intended to expedite the development and review of the immunotherapy, which is currently in a Phase 2b clinical trial. Topline data from the SAFEGUARD study is anticipated in the second half of 2027.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.